Recombinant Polyclonal Proteins for Zika Virus Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Zika virus lack effective FDA-approved vaccines or treatments, particularly due to challenges like antibody-dependent enhancement and batch-to-batch variation in plasma-derived hyperimmune globulins, which are limited by supply, impurities, and immunogenicity issues.
Innovation Solution
Development of recombinant polyclonal protein compositions (RPPs) such as recombinant Zika Immune Globulin (rZIG) with specific antigen binding proteins derived from Zika-infected peripheral blood cells, offering high specificity and neutralization titers, produced through advanced cell culture techniques to overcome these limitations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If plasma-derived hyperimmune globulins are used to treat Zika virus, then immediate therapeutic availability is achieved, but batch-to-batch variation and supply limitations occur
Solution Approach 1:
The patent creates recombinant copies of neutralizing antibodies through DNA sequencing and expression in mammalian cells. Instead of relying on plasma donations, the invention synthesizes identical antibody sequences recombinantly, ensuring consistent production across batches while maintaining the therapeutic efficacy of plasma-derived antibodies.
Solution Approach 2:
The patent transitions from a biological material source (plasma) to a controlled biomanufacturing process (recombinant expression). By changing the production parameters from donor-dependent plasma collection to standardized cell culture conditions, the invention eliminates batch-to-batch variation while ensuring reliable therapeutic availability.
2Speed
If plasma-derived hyperimmune globulins are used, then rapid response to emerging pathogens is achieved, but impurities and safety concerns arise
Solution Approach 1:
The patent extracts only the essential therapeutic component (neutralizing antibody sequences) from the complex plasma mixture. By sequencing and cloning specific B-cell receptor genes that encode neutralizing antibodies, the invention isolates the beneficial elements while leaving behind all impurities, infectious agents, and unwanted proteins present in whole plasma.
Solution Approach 2:
The invention creates purified recombinant copies of only the neutralizing antibody sequences through controlled expression in mammalian cells. This copying process produces highly pure therapeutic proteins without the contaminants, infectious viruses, or unwanted immunogenic materials found in plasma-derived products.
3Reliability
If animal-derived hyperimmune globulins are used, then therapeutic effect is achieved, but allergic reactions and antidrug antibodies occur
Solution Approach 1:
The patent changes the species origin parameter from non-human (animal plasma) to human (recombinant human antibodies expressed in human cell lines). By expressing human immunoglobulin sequences in human-derived or humanized mammalian cells, the invention produces therapeutics with human protein sequences that are immunologically compatible, eliminating allergic reactions and antidrug antibody formation associated with animal-derived products.
4Reliability
If plasma-derived drugs are used, then immediate treatment is available, but demand outstrips supply
Solution Approach 1:
The patent enables unlimited copying of therapeutic antibodies through recombinant DNA technology. Instead of being constrained by the finite supply of donor plasma, the invention uses DNA sequences that can be amplified and expressed indefinitely in mammalian cell cultures, allowing supply to meet any demand level without depleting donor resources.
Solution Approach 2:
The patent replaces the mechanical/biological limitation of plasma collection (dependent on donor availability and donation rates) with a scalable biomanufacturing system using mammalian cell expression. This substitution allows controlled, high-volume production that can be expanded according to demand by simply increasing cell culture scale, rather than being constrained by donor plasma supply rates.
Data Source
AI summary
Provided herein are compositions comprising recombinant polyclonal protein (RPP) derived from mammalian plasma cells and plasmablasts. Specifically, RPPs specific to Zika virus are provided. Also provided are the methods of using the RPP for treatment of viral infection and the methods of making the RPPs.